Arthritis drug can reduce mortality rate in Covid-19 patients by 71%: Study
In a major win against the Covid-19 researchers have identified that an Arthritis drug can help in reducing the mortality rate in elderly people by 71%. As per the findings, a daily pill of baricitinib along with standard care can reduce the deaths by 71% in Covid-19 patients with moderate or severe infection.
With almost a year since the coronavirus (Covid-19) disease was declared a pandemic, the viral disease continues to wreak havoc across the world. There is still very less we know about the disease and the researchers are working day and night to gather more and more information about the viral disease and its cure.
The drug is marketed under the name Olumiant and is available for rheumatoid arthritis for only three years now. (Shutterstock)
{{^htLoading}} {{/htLoading}}
In a major win against the Covid-19 researchers have identified that an Arthritis drug can help in reducing the mortality rate in elderly people by 71%. As per the findings, a daily pill of baricitinib along with standard care can reduce the deaths by 71% in Covid-19 patients with moderate or severe infection.
{{^usCountry}}{{/usCountry}}
The drug is marketed under the name Olumiant and is available for rheumatoid arthritis for only three years now.
The latest findings can be encouraging for medics as they are hoping the arthritis drug could help save most vulnerable to coronavirus that are elderly people.
The research is led by the researchers in Karolinska Institute in Sweden.
As many as 53,945,763 people have been infected by the Covid-19 across the world. Most of the fresh cases were reported from the United States and Europe. While 1,311,427 others have succumbed to the disease.
{{^htLoading}} {{/htLoading}}
{{^usCountry}}
Meanwhile, on vaccine front, US-based pharmaceutical company recently announced that the vaccine, it is developing in joint cooperation with Germany’s BioNTech is 90% effective in preventing infections in the ongoing Phase 3 trials.
{{/usCountry}}
{{#usCountry}}
Meanwhile, on vaccine front, US-based pharmaceutical company recently announced that the vaccine, it is developing in joint cooperation with Germany’s BioNTech is 90% effective in preventing infections in the ongoing Phase 3 trials.
{{/usCountry}}
The findings were based on an interim analysis conducted after 94 participants contracted the illness. The trial will continue until 164 cases have occurred. The preliminary results pave the way for the companies to seek an emergency-use authorization from regulators if further research shows the shot is also safe.
Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.
Get the latest World News, breaking headlines and global updates from the US, UK, Pakistan, Bangladesh, Russia and other countries. Follow major international events on Hindustan Times.
Get the latest World News, breaking headlines and global updates from the US, UK, Pakistan, Bangladesh, Russia and other countries. Follow major international events on Hindustan Times.
